Non-Alcoholic Steatohepatitis – Epidemiology Forecast to 2029

Pages: 35 Published: June 30, 2020 Report Code: GDHCER244-20

Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage (NIDDK, 2016). Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symptoms, and most people affected with the disease feel healthy and are unaware they have a problem (NIDDK, 2016).

GlobalData epidemiologists utilized primary research and comprehensive, country-specific data from peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the total and diagnosed prevalent cases of NASH. For all the 7MM, NASH cases were segmented by age and sex, and were then further segmented by NASH stage of fibrosis. Since obesity is a major risk factor for NASH, the historical, country-specific prevalence trends in obesity were incorporated to determine the prevalence trends in NASH.

GlobalData epidemiologists forecast that the total prevalent cases of NASH in the 7MM will grow by an annual growth rate (AGR) of 0.55% over the next 10 years, from 68,302,915 cases in 2019 to 72,059,723 cases in 2029. For diagnosed prevalent cases, GlobalData epidemiologists forecast that the 7MM will grow by an AGR of 3.07% over the next 10 years, from 26,124,484 cases in 2019 to 34,139,592 cases in 2029. For the stage of fibrosis in 2019, stages F0–F1 were the most common stages, representing 30.47% of diagnosed prevalent cases of NASH. GlobalData epidemiologists expect that the development of less-invasive diagnostic methods, increased physician awareness, and screening programs may drive the number of total and diagnosed prevalent cases higher. Additionally, genetic research has shown that PNPLA3 polymorphisms have a strong association with NAFLD, and therefore NASH, making it a future area of study.

Scope

The Non-Alcoholic Steatohepatitis Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and global trends of Non-Alcoholic Steatohepatitis (NASH) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report includes a 10-year epidemiological forecast for the total prevalent cases (both diagnosed and undiagnosed) of NASH segmented by age (0–17 years, 18–29, and by 10-year age groups up to 80 years and older) and sex. It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of NASH, which are further segmented by stage of fibrosis (F0–F1, F2, F3, and F4). In addition, the epidemiology model corresponding to this report provides the total and diagnosed prevalent cases of NAFLD in ages 18 years and older.

The NASH epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The NASH Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global NASH markets.

Quantify patient populations in the global NASH markets to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NASH therapeutics in each of the markets covered.

Understand magnitude of NASH population by stage of fibrosis.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Non-Alcoholic Steatohepatitis: Executive Summary

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.3.1 Total Prevalence of NASH (%)

3.3.2 Diagnosed Prevalence of NASH (%)

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Sources Not Used

3.4.3 Forecast Assumptions and Methods

3.4.4 Total Prevalent Cases of NASH

3.4.5 Diagnosed Prevalent Cases of NASH

3.4.6 Diagnosed Prevalent Cases of NASH by Stage of Fibrosis

3.5 Epidemiological Forecast for NASH (2019–2029)

3.5.1 Total Prevalent Cases of NASH

3.5.2 Diagnosed Prevalent Cases of NASH

3.5.3 Age-Specific Diagnosed Prevalent Cases of NASH

3.5.4 Sex-Specific Diagnosed Prevalent Cases of NASH

3.5.5 Diagnosed Prevalent Cases of NASH by Stage of Fibrosis

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of the Analysis

3.6.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 Primary Research – Prescriber Survey

4.3 About the Authors

4.3.1 Epidemiologist

4.3.2 Reviewers

4.3.3 Global Director of Therapy Analysis and Epidemiology

4.3.4 Global Head and EVP of Healthcare Operations and Strategy

4.4 About GlobalData

4.5 Contact Us

4.6 Disclaimer

List of Tables

Table 1: Summary of Newly Added Data Types

Table 2: Risk Factors and Comorbidities for NASH

Table 3: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: 7MM, Total Prevalent Cases of NASH, Both Sexes, 2019 and 2029

Figure 2: 7MM, Diagnosed Prevalent Cases of NASH, Both Sexes, 2019 and 2029

Figure 3: 7MM, Total Prevalence of NASH (%), Both Sexes, All Ages, 20092029

Figure 4: 7MM, Diagnosed Prevalence of NASH (%), Both Sexes, All Ages, 20092029

Figure 5: 7MM, Sources Used for NASH Total Prevalence

Figure 6: 7MM, Sources Used for Obesity Prevalence

Figure 7: 7MM, Sources Used for the Diagnosed Prevalent Cases of NASH and Diagnosed Prevalent Cases of NASH by Stage of Fibrosis

Figure 8: 7MM, Total Prevalent Cases of NASH, Both Sexes, All Ages, 2019

Figure 9: 7MM, Diagnosed Prevalent Cases of NASH, Both Sexes, All Ages, 2019

Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of NASH, Both Sexes, 2019

Figure 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of NASH, All Ages, 2019

Figure 12: 7MM, Diagnosed Prevalent Cases of NASH by Stage of Fibrosis, Both Sexes, All Ages, 2019

Frequently Asked Questions

$3995

Can be used by individual purchaser only

$11985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.